Dr Rebecca C Larsen, AUD | |
Hwy 160 M.p. 394.3, Kayenta, AZ 86033 | |
(928) 697-5134 | |
(928) 697-4030 |
Full Name | Dr Rebecca C Larsen |
---|---|
Gender | Female |
Speciality | Audiologist - Assistive Technology Practitioner |
Location | Hwy 160 M.p. 394.3, Kayenta, Arizona |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1073945341 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
231HA2400X | Audiologist - Assistive Technology Practitioner | DA8401 (Arizona) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Rebecca C Larsen, AUD Po Box 3446, Kayenta, AZ 86033-3446 Ph: (928) 697-5134 | Dr Rebecca C Larsen, AUD Hwy 160 M.p. 394.3, Kayenta, AZ 86033 Ph: (928) 697-5134 |
News Archive
When planes have a problem, analysts can usually figure out what went wrong. They simply check the plane's "black box," which records exactly what was happening to the plane at the time. Now, there's something similar for people. Under the leadership of NASA/Ames design engineer Carsten Mundt, researchers have developed a device that, Stanford electrical engineer and team member Greg Kovacs says, is a black box for human beings.
Research by psychologists at the University of Kent has found that a majority of people would endorse the use of revenge porn and that those who actually post it have a distinct personality profile.
The first melatonergic antidepressant - Valdoxan/Thymanax (agomelatine) - has received a positive opinion from the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) for its use in the treatment of adult patients with major depressive disorder (MDD).
Sunesis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). Sunesis is currently conducting two Phase 2 clinical trials of voreloxin in AML: a single-agent study, known as REVEAL-1, of voreloxin in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy and a study evaluating voreloxin in combination with cytarabine in relapsed/refractory AML.
​After an extensive review by a panel of top cancer experts, the National Cancer Institute (NCI) rated The Wistar Institute Cancer Center as "exceptional" and recommended renewal for Wistar's Support Grant with an award of $14.9 million over the next five years.
› Verified 2 days ago